BNP concentrations and cardiovascular adaptation in preterm and fullterm newborn infants

Mannarino, Savina; Garofoli, Francesca; Mongini, Elisa; Cerbo, Rosa Maria; Codazzi, Alessia Claudia; Tzialla, Chryssoula; Mazzucchelli, Iolanda; Perotti, Gianfranco; Tinelli, Carmine; Silvestri, Annalisa De; Manzoni, Paolo; Stronati, Mauro

doi:10.1016/j.earlhumdev.2010.04.003

Cited by 34 publications

(33 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The positive correlation between magnitude of ductal shunt by echocardiography and BNP levels has been reported [16,17,18]. We investigated the correlation between magnitude of ductal shunt and BNP levels at 12 and 24 h of age separately and could find that the BNP levels at 24 h of age have a higher correlation with magnitude of ductal shunt than BNP levels at 12 h of age.…”

Section: Discussionmentioning

confidence: 75%

Can Early B-Type Natriuretic Peptide Assays Predict Symptomatic Patent Ductus Arteriosus in Extremely Low Birth Weight Infants?

Lee

Shin²,

Park

et al. 2012

Neonatology

View full text Add to dashboard Cite

Background: Earlier and more accurate identification of a high-risk group of preterm infants that are likely to develop a hemodynamically significant patent ductus arteriosus (hsPDA) would allow specific targeting of early treatment and thus possibly minimize the morbidity and mortality associated with a PDA in extremely low birth weight (ELBW) infants. Objective: To investigate the predictability of B-type natriuretic peptide (BNP) for early targeted treatment of hsPDA in ELBW infants. Methods: 73 ELBW infants that underwent echocardiographic evaluation and plasma BNP measurement after birth were enrolled. 31 infants developed hsPDA (HsPDA group) and 42 infants did not develop hsPDA (nPDA group). Results: BNP levels of the HsPDA group were significantly higher than those of the nPDA group at 24 h of age (921 [318–2,133] vs. 152 [91–450] pg/ml) but not different at 12 h of age. BNP levels at 24 h of age were significantly correlated with the magnitudes of the ductal shunt but not at 12 h of age. The area under the receiver operator characteristic curve of BNP levels for prediction of hsPDA at 24 h of age was 0.830. At the cutoff BNP levels of 200 and 900 pg/ml at 24 h of age, sensitivity was 83.9 and 54.8% and specificity was 61.9 and 95.2%, respectively. Conclusions: BNP levels at 24 h of age can be used as a guide for early targeted treatment of hsPDA and avoid the unnecessary use of cyclooxygenase inhibitors in ELBW infants.

show abstract

Section: Discussionmentioning

confidence: 75%

Can Early B-Type Natriuretic Peptide Assays Predict Symptomatic Patent Ductus Arteriosus in Extremely Low Birth Weight Infants?

Lee

Shin²,

Park

et al. 2012

Neonatology

View full text Add to dashboard Cite

show abstract

“…It is secreted as an inactive precursor pro‐BNP, which is then cleaved into NT‐proBNP and BNP. NT‐proBNP is released into the circulation along with BNP from myocytes, and thus reflects BNP secretion . NT‐proBNP has a half‐life of 120 minutes, which is longer than BNP (20 minutes).…”

Section: Discussionmentioning

confidence: 99%

Role of NT‐proBNP in the prediction of moderate to severe Bronchopulmonary Dysplasia in preterm infants

Khan¹,

Concina

Schneider

et al. 2019

Pediatric Pulmonology

View full text Add to dashboard Cite

Objective The objective of the study was to determine the clinical utility of brain natriuretic peptide (NT‐proBNP) for prediction of moderate to severe bronchopulmonary dysplasia (BPD). We hypothesized that elevated NT‐proBNP levels at 4 weeks of postnatal age may predict the severity of BPD in preterm infants. Study Design The study design was a prospective observational study. The research team enrolled and followed a cohort of 70 infants with gestational age less than or equal to 30 weeks. The plasma NT‐proBNP levels were measured at the postnatal day 28th. We further followed and categorized infants into two groups. Infants with no or mild BPD (Group 1) and infants with moderate or severe BPD (Group 2). We compared plasma NT‐proBNP levels at 28th day of postnatal life between Groups 1 and 2. The difference in NT‐proBNP levels on day 28th between groups was used to predict the severity of BPD. Results Plasma NT‐proBNP was significantly elevated in Group 2 compared with Group 1, median (IQR) of 845 pg/mL (553, 1632) compared with 726 pg/mL (391, 923), P = 0.02. NT‐proBNP had a fair predictive accuracy (C statistics of 0.68) to determine moderate to severe BPD. Conclusion NT‐proBNP may be a useful biomarker in conjunction with clinical factors as a predictor of severe BPD. For future directions, the trend of NT‐proBNP in infants with BPD may have clinical significance in monitoring of the disease.

show abstract

“…Therefore, it causes volume overload and increased pulmonary vascular resistance as well as decrease in the systematic resistance which in return result in RDS (14). Some infants sickening to RDS possess a clinically significant shunt of PDA which is left open due to hypoxia, acidosis, secondary lung pressure increase in response to contraction of pulmonary venous pressure, systemic hypotension, immaturity and local secretion of prostaglandins due to the duct dilation; so it seems as if there is a relation between duct patency, airway inflammation and brochopulmonary dysplasia (BPD) (15,16).…”

Section: Introductionmentioning

confidence: 99%

Brain Natriuretic Peptide: A Predictor for Severity Respiratory Distress Syndrome in Newborns

et al. 2013

View full text Add to dashboard Cite

Background:Respiratory distress syndrome (RDS) is considered as one of the most popular prematurity-related respiratory problems and among the most prominent reasons of deaths in preterm infants. Objectives: Brain Natriuretic Peptide (BNP) is the secret of the volume and pressure overload response of the vessels and decreases due to resistance as well as rises in systemic vessels and also in decline of pulmonary artery pressure. In the present paper, BNP is considered as a biomarker for prediction of RDS scoring. Materials and Methods: In this case, 65 preterm infants under 37 weeks with an Apgar score more than seven and 65 healthy term infants were chosen. All of them were controlled for three days in NICU and then divided into 4 groups based on the RDS scoring and intensity, as well as chest x-ray findings; normal, mild, moderate, and severe. Serum BNP of all the infants was measured through ELISA kit and a questionnaire was filled up for each infant based on his/her demographic information and clinical findings. The collected data were analyzed by SPSS software based on the independent statistical t-test, one-sided variance analysis and X2. P < 0.05 was considered as the significant. Results:The study results revealed a significant difference between the two groups regarding the pregnancy age, weight and type of delivery between cases and control groups (P ≥ 0.05); but there was no significant difference between BNP in cases and control groups (P ≤ 0.05). However, the comparison between the mean of pregnancy weight, pregnancy age, and BNP based on RDS frequency among the patients was significant (P ≥ 0.05). Conclusions:The results of this study demonstrated that serum BNP level correlates with increased RDS scoring. Therefore, it is possible to use BNP as the prediction marker for the progressive changes of RDS which occur in premature infants.

show abstract

BNP concentrations and cardiovascular adaptation in preterm and fullterm newborn infants

Cited by 34 publications

References 17 publications

Can Early B-Type Natriuretic Peptide Assays Predict Symptomatic Patent Ductus Arteriosus in Extremely Low Birth Weight Infants?

Can Early B-Type Natriuretic Peptide Assays Predict Symptomatic Patent Ductus Arteriosus in Extremely Low Birth Weight Infants?

Role of NT‐proBNP in the prediction of moderate to severe Bronchopulmonary Dysplasia in preterm infants

Brain Natriuretic Peptide: A Predictor for Severity Respiratory Distress Syndrome in Newborns

Contact Info

Product

Resources

About